论文部分内容阅读
评价CVM_(26)-CAP方案交替使用治疗小细胞肺癌(SCLC)的近期疗效.方法 本组共包括我院1995年6月—1998年6月收治的可评价疗效的sclc48例.男38例,女10例.年龄28～70岁.全部病例均经细胞学及/或病理学证实.局限期(LD)37例,广泛期(ED)11例.均为初治病例,有可测量的临床和X线观察指标.可评价近期疗效.治疗采用CVM_(26)CAP两方案交替使用,4周期后评价疗效.结果 48例中.完全缓解6例(12.5%),部分缓解36例(75.0%),稳定4例(8.3%),进展2例(4.2%),总有效率为87.5%(42/48).主要毒性为消化道反应和骨髓抑制,临床观察病人可以耐受.结论 本方案有效率较高,可以推荐作为SCLC化疗的首选方案.
To evaluate the short-term efficacy of CVM_(26)-CAP regimen in the treatment of small cell lung cancer (SCLC). Methods This group included a total of 48 sclcs that were evaluated in our hospital between June 1995 and June 1998. Female 10 patients, age 28 to 70 years old. All cases were confirmed by cytology and/or pathology. 37 patients were with limited period (LD) and 11 patients with extensive period (ED). They were all cases of primary treatment and had measurable clinical And X-ray observation indicators. Can evaluate the short-term efficacy. Treatment using CVM_ (26) CAP two programs alternately, after 4 cycles to evaluate the efficacy. Results Of 48 cases. Complete remission in 6 cases (12.5%), partial remission in 36 cases (75.0% ), Stable in 4 cases (8.3%), Progress in 2 cases (4.2%), The total effective rate was 87.5% (42/48). The main toxicity was digestive tract reaction and myelosuppression, clinical observation patients can tolerate. Conclusions High efficiency, can be recommended as the first choice for SCLC chemotherapy.